Objetivo
Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical practice for patients with mRCC dramatically. Both response and toxicity to these expensive drugs is, however, extremely variable. With an increasing number of compounds becoming available, choice of compounds and sequence is becoming extraordinary challenging. Classical patient and tumor characteristics appear to have poor predictive ability. The aim of this project is to identify germline genetic markers that predict response and toxicity (by the use of high-resolution whole genome SNP arrays in groups of hundreds of patients treated with different agents), identify expression and epigenetic markers in tumors that predict response (by comparing expression and methylome arrays and kinase profiles in frozen tumor tissue from groups of patients who do (N=30) and do not (N=30) respond to different agents), to integrate these data from different platforms by means of bioinformatics and to conduct focused functional studies on the results in order to improve understanding of the critical molecular and resistance pathways involved. A large European consortium that has recruited and will recruit large numbers of patients ensures that the new markers identified in a first discovery phase can be tested in a subsequent replication phase. We have the ambition to define new validated risk stratification criteria to be used in personalized patient management. These criteria allow prediction of individual therapy response and resistance and will enable the monitoring of successful treatment outcome while reducing unnecessary drug use and expense.
Ámbito científico
Convocatoria de propuestas
FP7-HEALTH-2010-two-stage
Consulte otros proyectos de esta convocatoria
Régimen de financiación
CP-FP - Small or medium-scale focused research projectCoordinador
6525 XZ Nijmegen
Países Bajos
Ver en el mapa
Participantes (14)
2333 ZA Leiden
Ver en el mapa
CB2 1TN Cambridge
Ver en el mapa
La participación finalizó
07747 Jena
Ver en el mapa
1150 WIEN
Ver en el mapa
101 Reykjavik
Ver en el mapa
08908 L'Hospitalet De Llobregat
Ver en el mapa
5211 HH S HERTOGENBOSCH
Ver en el mapa
1066 CX Amsterdam
Ver en el mapa
75654 Paris
Ver en el mapa
020021 Bucuresti
Ver en el mapa
53113 Bonn
Ver en el mapa
CB2 0QQ Cambridge
Ver en el mapa
28001 Madrid
Ver en el mapa
66123 Saarbrucken
Ver en el mapa